Allergy & Immunology CE Activities

Optimizing Biologic Therapy in Children with Moderate-to-Severe Atopic Dermatitis: A Care Team Forum®

1.0 CE Credit(s)

Updates in Hereditary Angioedema Care from the HAEA

1.0 CE Credit(s)

Reinforcing the Roles of Biologic Therapy and Interprofessional Care in Improving Patient Outcomes (1 of 3)

0.25 CE Credit(s)

ALLERGY & iMMUNOLOGY blog

6 Ways to Personalize Your Patient’s Asthma Treatment Plan

Asthma management is increasingly becoming more personalized. Here are 6 ways you can help personalize treatment for your patients with asthma that is severe or difficult to control.

Allergy & Immunology, Pulmonology
Blog

Try These Diets for Your Patients with EoE

In infancy, you can see feeding problems, and as the child progresses to adulthood, you will see them complain about vomiting, abdominal pain, difficulty swallowing, food impaction, and all of this may cause them to avoid eating certain foods, eat very slowly, or avoid social situations where food is involved.

Allergy & Immunology
Blog

RMEI Presentations

4 Years, 16 Live & Online Activities, 6000+ Clinicians: What we’ve learned so far

LATEST ALLERGY & IMMUNOLOGY ARTICLES

Latest Allergy & Immunology Articles

A Holy Grail — The Prediction of Protein Structure September 21, 2023
The 2023 Lasker Award for Basic Medical Research underscores the value of an AI system that predicts the three-dimensional structure of proteins from the one-dimensional sequence of their amino acids.
Russ B. Altman
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH September 14, 2023
In this phase 2b, placebo-controlled trial involving patients with nonalcoholic steatohepatitis, pegozafermin, a long-acting glycopegylated FGF21 analogue, reduced fibrosis at 24 weeks.
Rohit Loomba, Arun J. Sanyal, Kris V. Kowdley, Deepak L. Bhatt, Naim Alkhouri, Juan P. Frias, Pierre Bedossa, Stephen A. Harrison, Donald Lazas, Robert Barish, Mildred D. Gottwald, Shibao Feng, Germaine D. Agollah, Cynthia L. Hartsfield, Hank Mansbach, Maya Margalit, Manal F. Abdelmalek
Pegozafermin for NASH — A Sprint to Start a Marathon September 14, 2023
Pharmacotherapy in patients with nonalcoholic steatohepatitis (NASH) has been a frustrating endeavor, with failures outnumbering successes by some margin, even in late-phase clinical trials. The complex pathobiologic features of NASH, the slow and variable natural history of the disease, and the nefarious nature of assessing histologic end points have contributed...
Mary E. Rinella

RMEI LIGHTNING TALKS

4 Years, 16 Live & Online Activities, 6000+ Clinicians: What we've learned so far

RMEI has released pairings of live and online programs approximately twice per year since 2016 grouped into “phases” which share clinical areas of focus and are based on findings from the previous phase of education. In total, 16 activities have launched to date with 4 activities currently live. The purpose of this analysis is to better understand the impact of multi-year iterative education on a clinical audience. Presented at: Society for Academic CME (SACME), virtual, February 2021; Accreditation Council for Continuing Medical Education (ACCME), virtual, April 2021.

Allergy & Immunology
2021

Effectiveness of 5-year IBD Provider Online Educational Intervention Program

There is considerable practice variability among providers caring for inflammatory bowel disease (IBD) patients. Limited data exists on the effectiveness of educational interventions targeting IBD providers to address these gaps. We report outcomes for a 5-year provider education training program which culminated in an enduring online education resource and clinical decision support tool.

Gastroenterology
2021